![]() Stanztab,
Unigen Lifesciences, Bangkok Chemical name: stanozolol Thailand FDA approved registration # 1C 107/51 –- Approved May 16th 2008 Stanztab10 is an oral androgen, a derivative of Dihydrotestosterone (DHT). Stanozolol was originally developed to treat hereditary angioedema. As with most androgens, stanozolol will help to create a state of anabolism and contribute to a significant increase in muscle tissue. Structurally, stanozolol is not capable of converting into estrogen therefore will not contribute to water retention which may be the case with other androgens. Also unlike most anabolic steroids, is not esterified. Anabolic steroids such as Stanozolol are synthetic derivatives of testosterone. Stanozolol has been found to increase low-density lipoproteins and decrease high-density lipoproteins. These changes are not associated with any increase in total cholesterol or triglyceride levels and revert to normal on discontinuation of treatment. Hereditary angioedema (HAE) is an autosomal dominant disorder caused by a deficient or nonfunctional C1 esterase inhibitor (C1 INH) and clinically characterized by episodes of swelling of the face, extremities, genitalia, bowel wall, and upper respiratory tract. In small clinical studies, Stanozolol was effective in controlling the frequency and severity of attacks of angioedema and in increasing serum levels of C1 INH and C4. Stanozolol is not effective in stopping HAE attacks while they are under way. The effect of stanozolol on increasing serum levels of C1 INH and C4 may be related to an increase in protein anabolism. Stanztab 10 may increase sensitivity to anticoagulants; therefore, dosage of anticoagulants may have to be decreased in order to maintain the prothrombin time at the desired therapeutic level. Side effects Hepatic: Cholestatic jaundice with rarely, hepatic necrosis and death. Hepatocellular neoplasms and peliosis hepatis have been reported in association with long term androgenic anabolic steroid. Reversible changes in liver function tests also occur including increased bromsulphalein (BSP) retention and increases in serum bilirubin, glutamic oxaloacetic transaminase (SGOT), and alkaline phosphatase. Genitourinary System (Prepubertal men): Phallic enlargement and increased frequency of erections. Genitourinary System (Post pubertal men): Inhibition of testicular functions, testicular atrophy, and oligospermia, impotence, chronic priapism, epididymitis and bladder irritability. Genitourinary System (Women): Clitoral enlargement, menstrual irregularities. In both sexes: increased or decreased libido. CNS: Habituation, excitation, insomnia, and depression. Gastrointestinal: Nausea, vomiting, diarrhea. Hematologic: Bleeding in patients on concomitant anticoagulant therapy. Breast: Gynecomastia. Larynx: Deepening of the voice in women. Hair: Hirsutism and male pattern baldness in women. Skin: Acne (especially in women and prepubertal boys.) Skeletal: Premature closure of epiphyses in children. Fluid and Electrolytes: Edema, retention of serum electrolytes (Sodium chloride, potassium, phosphate, and calcium). From Stanztab 10 go back to home page FAQ Pricelists Terms & Conditions Fake Steroids Home Page | ||